Investigational Hemophilia A Treatment Shows Positive Phase 3 Trial Results

New data regarding Novo Nordisk's experimental hemophilia A treatment, denecimig, has been published in the New England Journal of Medicine. The Phase 3 FRONTIER2 trial indicated that the drug significantly reduced bleeding rates in patients with hemophilia A, regardless of inhibitor status. These findings represent a promising development for individuals living with this condition.